2-arachidonoylglycerol

2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.

Cross Reference

Introduction

To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with 2-arachidonoylglycerol?

2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol

MeSH term MeSH ID Detail
Stomach Ulcer D013276 75 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Pain D010146 64 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hypotension D007022 41 associated lipids
Hepatic Encephalopathy D006501 9 associated lipids
Weight Gain D015430 101 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Glioma D005910 112 associated lipids
Obesity D009765 29 associated lipids
Alzheimer Disease D000544 76 associated lipids
Peripheral Nervous System Diseases D010523 33 associated lipids
Nervous System Diseases D009422 37 associated lipids
Brain Edema D001929 20 associated lipids
Starvation D013217 47 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Brain Ischemia D002545 89 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Epilepsy D004827 35 associated lipids
Nerve Degeneration D009410 53 associated lipids
Myocardial Reperfusion Injury D015428 20 associated lipids
Hyperalgesia D006930 42 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Morphine Dependence D009021 9 associated lipids
Catalepsy D002375 30 associated lipids
Hyperkinesis D006948 11 associated lipids
Hyperinsulinism D006946 27 associated lipids
Fatty Liver, Alcoholic D005235 11 associated lipids
Hypothermia D007035 19 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Head Injuries, Closed D016489 5 associated lipids
Brain Concussion D001924 5 associated lipids
Encephalitis D004660 15 associated lipids
Memory Disorders D008569 33 associated lipids
Acute Lung Injury D055371 33 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Neuralgia D009437 28 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Fragile X Syndrome D005600 5 associated lipids
Cholangiocarcinoma D018281 7 associated lipids
Neuromyelitis Optica D009471 2 associated lipids
Acute Pain D059787 3 associated lipids
Fetal Nutrition Disorders D048070 1 associated lipids
Per page 10 20 50 100 | Total 51

PubChem Associated disorders and diseases

What pathways are associated with 2-arachidonoylglycerol

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with 2-arachidonoylglycerol?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with 2-arachidonoylglycerol?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with 2-arachidonoylglycerol?

Knock-out

Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with 2-arachidonoylglycerol

Download all related citations
Per page 10 20 50 100 | Total 1060
Authors Title Published Journal PubMed Link
Wang J and Ueda N Biology of endocannabinoid synthesis system. 2009 Prostaglandins Other Lipid Mediat. pmid:19126434
Vignali M et al. The endocannabinoid anandamide inhibits potassium conductance in rat cortical astrocytes. 2009 Glia pmid:19031444
Straiker A and Mackie K Cannabinoid signaling in inhibitory autaptic hippocampal neurons. 2009 Neuroscience pmid:19501632
Yates ML and Barker EL Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. 2009 Mol. Pharmacol. pmid:19389920
Hill MN et al. Circulating endocannabinoids and N-acyl ethanolamines are differentially regulated in major depression and following exposure to social stress. 2009 Psychoneuroendocrinology pmid:19394765
Bajo M et al. Differential alteration of hippocampal excitatory synaptic transmission by cannabinoid ligands. 2009 J. Neurosci. Res. pmid:18816788
Bisogno T et al. Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. 2009 Biochim. Biophys. Acta pmid:19027877
Long JZ et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. 2009 Nat. Chem. Biol. pmid:19029917
Schlosburg JE et al. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. 2009 AAPS J pmid:19184452
Koppel J et al. Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. 2009 Lipids Health Dis pmid:19144193
Nyilas R et al. Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia. 2009 Eur. J. Neurosci. pmid:19453631
Garcia-Ovejero D et al. The endocannabinoid system is modulated in response to spinal cord injury in rats. 2009 Neurobiol. Dis. pmid:18930143
Wakley AA and Rasmussen EB Effects of cannabinoid drugs on the reinforcing properties of food in gestationally undernourished rats. 2009 Pharmacol. Biochem. Behav. pmid:19602424
Izzo AA et al. Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re-feeding. 2009 Br. J. Pharmacol. pmid:19371345
Catani MV et al. Expression of the endocannabinoid system in the bi-potential HEL cell line: commitment to the megakaryoblastic lineage by 2-arachidonoylglycerol. 2009 J. Mol. Med. pmid:18820887
Jiang LS et al. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. 2009 Cardiovasc. Res. pmid:19074161
Avraham Y et al. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor agonist, in various rat tissues during the evolution of experimental cholestatic liver disease. 2008 Jul-Aug Prostaglandins Leukot. Essent. Fatty Acids pmid:18771906
Hill MN et al. Prolonged glucocorticoid treatment decreases cannabinoid CB1 receptor density in the hippocampus. 2008 Hippocampus pmid:18058925
Maccarrone M et al. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. 2008 Nat. Neurosci. pmid:18204441
Hashimotodani Y et al. Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release. 2008 Neuropharmacology pmid:17655882
Mátyás F et al. Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. 2008 Neuropharmacology pmid:17655884
Starowicz KM et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. 2008 Obesity (Silver Spring) pmid:18239598
Shimizu T and Yokotani K Bidirectional roles of the brain 2-arachidonoyl-sn-glycerol in the centrally administered vasopressin-induced adrenomedullary outflow in rats. 2008 Eur. J. Pharmacol. pmid:18234185
Moreira FA et al. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. 2008 Neuropharmacology pmid:17709120
Tam J et al. The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. 2008 FASEB J. pmid:17704191
Chiu CQ and Castillo PE Input-specific plasticity at excitatory synapses mediated by endocannabinoids in the dentate gyrus. 2008 Neuropharmacology pmid:17706254
Vellani V et al. Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. 2008 Neuropharmacology pmid:18329052
Engeli S et al. Peripheral endocannabinoid system activity in patients treated with sibutramine. 2008 Obesity (Silver Spring) pmid:18356837
Guindon J and Hohmann AG A physiological role for endocannabinoid-derived products of cyclooxygenase-2-mediated oxidative metabolism. 2008 Br. J. Pharmacol. pmid:18297102
Oláh M et al. The role of endocannabinoids in the regulation of luteinizing hormone and prolactin release. Differences between the effects of AEA and 2AG. 2008 Mol. Cell. Endocrinol. pmid:18308464
Hu SS et al. Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. 2008 Br. J. Pharmacol. pmid:18297109
Hill MN et al. Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. 2008 Pharmacopsychiatry pmid:18311684
Palkovits M et al. Regional distribution and effects of postmortal delay on endocannabinoid content of the human brain. 2008 Neuroscience pmid:18343585
Nomura DK et al. Activation of the endocannabinoid system by organophosphorus nerve agents. 2008 Nat. Chem. Biol. pmid:18438404
Bisogno T Endogenous cannabinoids: structure and metabolism. 2008 J. Neuroendocrinol. pmid:18426492
Rubio M et al. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. 2008 Neuropharmacology pmid:18371990
Di Marzo V and Maccarrone M FAAH and anandamide: is 2-AG really the odd one out? 2008 Trends Pharmacol. Sci. pmid:18394720
Solinas M et al. The endocannabinoid system in brain reward processes. 2008 Br. J. Pharmacol. pmid:18414385
Richardson D et al. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. 2008 Arthritis Res. Ther. pmid:18416822
Palmer JA et al. Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse. 2008 Neuroscience pmid:18541380
Di Marzo V Endocannabinoids: synthesis and degradation. 2008 Rev. Physiol. Biochem. Pharmacol. pmid:18481028
Pertwee RG Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. 2008 Addict Biol pmid:18482430
Di Filippo M et al. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis. 2008 J. Neurol. Neurosurg. Psychiatr. pmid:18535023
Awumey EM et al. Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries. 2008 Am. J. Physiol. Heart Circ. Physiol. pmid:18375719
Ellgren M et al. Dynamic changes of the endogenous cannabinoid and opioid mesocorticolimbic systems during adolescence: THC effects. 2008 Eur Neuropsychopharmacol pmid:18674887
Placzek EA et al. Mechanisms for recycling and biosynthesis of endogenous cannabinoids anandamide and 2-arachidonylglycerol. 2008 J. Neurochem. pmid:18778304
Placzek EA et al. Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. 2008 Neuropharmacology pmid:18760289
Qin N et al. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. 2008 J. Neurosci. pmid:18550765
Muccioli GG and Stella N An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain. 2008 Anal. Biochem. pmid:17981259
Thiemann G et al. The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. 2008 Behav. Brain Res. pmid:17988751